Northeast Investment Management lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,737 shares of the medical research company’s stock after purchasing an additional 2,621 shares during the period. Thermo Fisher Scientific comprises approximately 1.9% of Northeast Investment Management’s investment portfolio, making the stock its 15th largest holding. Northeast Investment Management’s holdings in Thermo Fisher Scientific were worth $21,897,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. Chicago Partners Investment Group LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $108,000. Shine Investment Advisory Services Inc. bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $113,000. Ropes Wealth Advisors LLC raised its stake in Thermo Fisher Scientific by 15.8% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 97 shares during the period. Atlantic Trust LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $138,000. Finally, Grove Bank & Trust raised its stake in Thermo Fisher Scientific by 19.9% in the 2nd quarter. Grove Bank & Trust now owns 860 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 143 shares during the period. Institutional investors own 86.16% of the company’s stock.
Shares of Thermo Fisher Scientific Inc. (TMO) opened at $192.27 on Monday. The stock has a market capitalization of $77,099.31, a P/E ratio of 21.13, a price-to-earnings-growth ratio of 1.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. Thermo Fisher Scientific Inc. has a 52 week low of $139.88 and a 52 week high of $201.20.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total value of $9,419,500.00. Following the completion of the sale, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.49% of the stock is owned by corporate insiders.
Several equities research analysts have recently weighed in on TMO shares. Cowen reiterated a “buy” rating and set a $200.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 1st. Argus reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target on the stock in a research report on Thursday, September 7th. Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target on the stock. Finally, Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus price target of $205.21.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.